Mengchang Yang
Welcome,         Profile    Billing    Logout  
 14 Trials 
18 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wang, Yi
TE-ITP, NCT05583838: A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts

Active, not recruiting
4
157
RoW
rhTPO, Recombinant human thrombopoietin, TPIAO, Eltrombopag, Eltrombopag olamine
Institute of Hematology & Blood Diseases Hospital, China, The Second Hospital of Hebei Medical University, Xijing Hospital, The Affiliated Hospital of Inner Mongolia Medical University, The Second Affiliated Hospital of Kunming Medical University, Second Affiliated Hospital of Guangzhou Medical University, Shaanxi Provincial People's Hospital, Henan Cancer Hospital, North China University of Science and Technology Affiliated Hospital, The Second Affiliated Hospital of Dalian Medical University, Second Hospital of Shanxi Medical University, The Second Affiliated Hospital of Harbin Medical University, Shenyang Sunshine Pharmaceutical Co., LTD., First Affiliated Hospital of Xinjiang Medical University, People's Hospital of Xinjiang Uygur Autonomous Region, Kashgar 1st People's Hospital, Xi'an Central Hospital, Beijing Public Health Foundation, Yuyao People's Hospital of Zhejiang Province
Previously Treated Primary Immune Thrombocytopenia
02/24
07/24
NCT05182463: Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients

Recruiting
4
5000
RoW
Peginterferon Alfa-2B, Nucleoside Analogs
Third Affiliated Hospital, Sun Yat-Sen University
Hepatitis B, Chronic
12/26
11/29
NCT05003245: Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD

Recruiting
3
388
RoW
HLX04-O,recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection, Lucentis
Shanghai Henlius Biotech
Age Related Macular Degeneration
08/23
03/24
LUNA3, NCT04562766 / 2020-002063-60: Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)

Recruiting
3
194
Europe, Canada, Japan, US, RoW
Rilzabrutinib, PRN1008, Placebo, PRN1008 Placebo
Principia Biopharma, a Sanofi Company, Principia Biopharma, Inc.
Immune Thrombocytopenia
06/25
11/26
NCT06434467: The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma

Not yet recruiting
3
83
RoW
Nelarabine injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
T-lymphoblastic Leukemia, T-lymphoblastic Lymphoma
12/25
05/26
METIS, NCT02831959: Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).

Active, not recruiting
3
270
Europe, Canada, US, RoW
NovoTTF-200M device, Best Standard of Care
NovoCure GmbH
Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
12/24
12/24
NCT06004856: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia

Recruiting
3
195
RoW
Orelabrutinib, Placebo
Beijing InnoCare Pharma Tech Co., Ltd.
Chronic Primary Immune Thrombocytopenia (ITP)
12/25
04/26
NCT05709093: A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)

Recruiting
3
552
RoW
Lemzoparlimab+Azacitidine (AZA), Azacitidine (AZA)
TJ Biopharma Co., Ltd.
Myelodysplastic Syndromes(MDS)
03/27
03/27
GMCAII, NCT06221683: Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML

Recruiting
2
500
RoW
Homoharringtonine, Homoharringtonine injection, Cytarabine, Cytosar, Etoposide, Etoposide injection, Venetoclax, Venclexta, Mitoxantrone hydrochloride liposome, Mitoxantrone hydrochloride liposome injection, Recombinant Human Granulocyte Colony-Stimulating Factor, Recombinant Human Granulocyte Colony-Stimulating Factor Injection, Idarubicin Hydrochloride, Idarubicin hydrochloride injection, Sorafenib, Nexavar, Gilteritinib, Xospata Pill, Avapritinib, AYVAKIT
Children's Hospital of Soochow University
AML, Childhood, Acute Myeloid Leukemia
12/28
12/29
NCT05614531: Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients With Spinal Muscular Atrophy Type 1

Recruiting
1/2
12
RoW
EXG001-307 injection
Hangzhou Jiayin Biotech Ltd
Spinal Muscular Atrophy Type I
03/25
03/25
03-OHD-104, NCT05275439: Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML

Recruiting
1
160
Europe, Canada, US
SL-172154, Azacitidine, Venetoclax
Shattuck Labs, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndromes
04/25
12/25
NCT05294679: Explore the Clinical Application Value of Ciprofol in Painless Colonoscopy

Completed
N/A
110
RoW
Propofol, Ciprofol
Sichuan Provincial People's Hospital
Induction of Anaesthesia
12/22
04/23
CRGGC, NCT04140552: Chinese Research Group of Gallbladder Cancer

Recruiting
N/A
10000
RoW
Shanghai Jiao Tong University School of Medicine, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, First Affiliated Hospital Bengbu Medical College, LanZhou University, Henan Cancer Hospital, The First Affiliated Hospital of Zhengzhou University, The Second Affiliated Hospital of Harbin Medical University, First Affiliated Hospital of Harbin Medical University, Harbin Medical University, The First Hospital of Jilin University, Second Hospital of Jilin University, China-Japan Union Hospital, Jilin University, The First People's Hospital of Changzhou, Changzhou No.2 People's Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, The First People's Hospital of Taicang, Wuxi Second People's Hospital, Xuzhou Central Hospital, Second Affiliated Hospital of Suzhou University, Affiliated Hospital of Nantong University, The First People's Hospital of Nantong, The Affiliated Hospital of Xuzhou Medical University, Second Affiliated Hospital of Nanchang University, The First Affiliated Hospital of Nanchang University, Jiangxi Provincial People's Hopital, Shengjing Hospital, Baotou Central Hospital, Qinghai People's Hospital, Changzhi Medical College, The First Affiliated Hospital of Shanxi Medical University, Shanxi Provincial Cancer Hospital, First Affiliated Hospital Xi'an Jiaotong University, Eastern Hepatobiliary Surgery Hospital, Shanghai Fengxian District Central Hospital, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Zhongshan Hospital, Shanghai Pudong Hospital, Central Hospital of Minhang District, Shanghai, Putuo District People's Hospital of Shanghai, Xinhua (Chongming) Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Tianjin Medical University Cancer Hospital, First Affiliated Hospital of Xinjiang Medical University, The First Affiliated Hospital of Kunming Medical College, Yinzhou Hospital Affiliated to Medical School of Ningbo University, Shaoxing Second Hospital, Shaoxing People's Hospital, First Affiliated Hospital of Wenzhou Medical University, Sir Run Run Shaw Hospital, Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Cancer Hospital, Huizhou Municipal Central Hospital, Ningbo No. 1 Hospital, People's Hospital of Hunan Province, Hainan People's Hospital, Taizhou Municipal Hospital, Xinghua City People's Hospital, Tongliao City Hospital, Jiangxi Provincial Cancer Hospital, Shandong Provincial Hospital, Qilu Hospital of Shandong University, The Affiliated Hospital of Qingdao University, Xijing Hospital
Gallbladder Neoplasms
12/22
12/25
NCT04171635: Quantitative Susceptibility Mapping (QSM) to Guide Iron Chelating Therapy

Recruiting
N/A
42
US
Quantitative Susceptibility Mapping (QSM) Magnetic Resonance Imaging (MRI), R2* Magnetic Resonance Imaging (MRI)
Weill Medical College of Cornell University, Columbia University, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
MRI Scans
07/24
01/25
PEPAD, NCT06369584: Prone Position During ECMO in Pediatric Patients With Severe ARDS

Recruiting
N/A
7
RoW
prone position
Seventh Medical Center of PLA General Hospital, Gansu Provincial Maternal and Child Health Care Hospital, Xian Children's Hospital, People's Hospital of Guangxi, Henan Provincial People's Hospital, Guangdong Provincial People's Hospital, Shenzhen Bao'an Maternal and Child Health Hospital, Zhengzhou Children's Hospital
Pediatric Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation
05/25
07/25
NCT06035250: AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy

Recruiting
N/A
200
Europe, RoW
Neoadjuvant Chemotherapy
Chinese Academy of Sciences, Peking University Cancer Hospital & Institute, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Yunnan Cancer Hospital, Henan Cancer Hospital, Zhenjiang First People's Hospital, First Hospital of China Medical University, Cancer Hospital of Guangxi Medical University, Peking University People's Hospital, Tianjin Medical University Cancer Institute and Hospital, The First Affiliated Hospital of Zhengzhou University, Nanfang Hospital, Southern Medical University, The Affiliated Hospital of Qingdao University, Ruijin Hospital, Sixth Affiliated Hospital, Sun Yat-sen University, Peking Union Medical College Hospital, Xiangya Hospital of Central South University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, The First Affiliated Hospital of Soochow University, First Affiliated Hospital, Sun Yat-Sen University, Fujian Medical University Union Hospital, Fujian Cancer Hospital, San Raffaele University Hospital, Italy
Gastric Cancer, Image, Pathology
08/24
12/29
NCT05157737: Clinical Phenotype and Omics Study of KCNQ2-related Epilepsy

Recruiting
N/A
200
RoW
Electrophysiological detection of KCNQ2 mutation, Multi-modal brain image and EEG, Omics testing
Fudan University
KCNQ2-related Epilepsy
12/23
12/24
NCT05243121: Artificial Intelligence Analysis for Magnetic Resonance Imaging in Screening and Diagnosis of Breast Cancer

Recruiting
N/A
5000
RoW
MRI
Peking University People's Hospital
Breast Neoplasms, Magnetic Resonance Imaging
09/25
09/25

Download Options